ReviewClinical interventions in aging2026
Advances in Therapeutic Drug Monitoring and Pharmacokinetic Researches of Oxazolidinone Antibacterial Agents in the Elderly Patients.
Review in Clinical interventions in aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Elderly patients are at increased risk of infection with methicillin-resistant Methods: This review synthesized evidence from published and ongoing studies examining the TDM and PK studies of linezolid, contezolid and tedizolid in elderly patients, encompassing investigations into drug concentrations monitoring, PK parameters, and population PK studies. No date restrictions were applied to the study selection. Results: The distinct pathophysiology of elderly patients leads to significant alterations in the PK characteristics of various antibacterial agents, necessitating individualized dosage adjustments. In this population, linezolid exhibits a prolonged half-life, markedly decreased clearance, and elevated risk of severe overexposure. Therefore, its dosage requires adjustment based on renal function and age. Contezolid exhibits comparable pharmacokinetics in patients aged 65-74 years to younger adults; however, in patients aged 80 and above, its time to peak concentration is delayed, elimination is accelerated, while C Conclusion: The PK characteristics of oxazolidinone antibiotics may be altered in the elderly population. TDM and model-informed precision dosing (MIPD) are crucial approaches for achieving individualized dosing strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.